Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal; Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed advanced solid tumors relapsed or refractory to standard therapy or for whom no standard therapy exists.

• ECOG Performance Status of 0 or 1;

• Total IGF-1 level ≥100 ng/ml;

• ECOG Performance Status of 0 or 1

• Adequate bone marrow, renal, and hepatic function

Exclusion Criteria:

• Concurrent treatment with any antitumor agents with the exception of LHRH agnosits for prostate cancer patients

• Treatment with any other investigational therapy within 4 weeks prior to study treatment

• Major surgery within 4 weeks of study treatment

• Prior treatment that may increase the risk of cardiac complications

• Ongoing cardiac dysrhythmias of NCI CTCAE Grade 2 or greater

• Significant active cardiac disease, including hypertension that cannot be controlled by medications

• Greater than three (3) prior lines of cytotoxic therapy;

• Active infection

• Prior IGF-IR targeted therapy;